top_banner
floatmenu_left Home Home   Drug Dictionary Drug Dictionary   Cancer Dictionary Cancer Dictionary   Links Links floatmenu_right
E-mail this page   Print this page
Cancer News

Keytruda Significantly Improved Recurrence-Free Survival in Patients with Stage 3 Melanoma

CancerConnect News:  The European Organisation for Research and Treatment of Cancer (EORTC), today announced that the phase 3 EORTC1325/KEYNOTE-054 trial investigating Keytruda (pembrolizumab), an anti-PD-1 precision immunotherapy for surgically resected high-risk melanoma, met the primary endpoint of improving recurrence-free survival.

Adjuvant Therapy in Melanoma

Melanoma is separated into five staging categories (stages 0-4).  Stage III melanoma is a cancer that has spread to the regional lymph nodes but has not yet spread to distant lymph nodes or to other parts of the body (metastasized).  Current standard treatment of stage III melanoma is surgical resection of the primary tumor as well as the involved lymph nodes. Despite surgical removal of the cancer however, most patients experience disease recurrence and progress to metastatic disease. By five years, the majority of stage IIIb and IIIc patients (68% and 89%, respectively) experience disease recurrence. There remains an unmet need for adjuvant therapy administered following surgery to reduce the risk of the cancer spreading.

About EORTC1325/KEYNOTE-054

The KEYNOTE-054 clinical trial evaluated adjuvant therapy with Keytruda compared to placebo in patients with resected high-risk stage IIIA, B, or C melanoma.  In total, the study enrolled 1,019 patients who were treated with either Keytruda or a placebo for up to 1 year. This represents a total of 18 outpatient administrations.

This interim analysis demonstrates that Keytruda delayed the time to a melanoma recurrence.  Keytruda is the second “checkpoint inhibitor” demonstrated to improve the treatment of stage III melanoma.  The United States Food and Drug Administration recently granted approval to Opdivo (nivolumab), another “checkpoint inhibitor”  for the adjuvant treatment of melanoma.  Opdivo significantly improved recurrence-free survival at 18 months (66%) compared to standard treatment with Yervoy® (ipilimumab), (53%) in patients with resected Stage III or Stage IV melanoma.

Keytruda and Opdivo are both precision cancer medicines that belong to a new class of medicines called PD-1 inhibitors that have generated great excitement for their ability to help the immune system recognize and attack cancer. PD-1 is a protein that inhibits certain types of immune responses. Drugs that block PD-1 may enhance the ability of the immune system to fight cancer. These so call “checkpoint inhibitors” work by blocking PD-1.  Additional clinical trials will further evaluate how best to use these new medications; whether best used alone, or in combination, and the optimal duration of therapy remain unanswered questions.

References:

  1. http://www.mrknewsroom.com/news-release/oncology/mercks-Keytruda-pembrolizumab-significantly-improved-recurrence-free-survival-
  2. http://news.cancerconnect.com/fda-approves-opdivo-adjuvant-treatment-melanoma/

Copyright © 2018 CancerConnect. All Rights Reserved.

CancerConnect News:  The European Organisation for Research and Treatment of Cancer (EORTC), today announced that the phase 3 EORTC1325/KEYNOTE-054 trial investigating Keytruda (pembrolizumab), an anti-PD-1 precision immunotherapy for surgically resected high-risk melanoma, met the primary endpoint of improving recurrence-free survival.

Adjuvant Therapy in Melanoma

Melanoma is separated into five staging categories (stages 0-4).  Stage III melanoma is a cancer that has spread to the regional lymph nodes but has not yet spread to distant lymph nodes or to other parts of the body (metastasized).  Current standard treatment of stage III melanoma is surgical resection of the primary tumor as well as the involved lymph nodes. Despite surgical removal of the cancer however, most patients experience disease recurrence and progress to metastatic disease. By five years, the majority of stage IIIb and IIIc patients (68% and 89%, respectively) experience disease recurrence. There remains an unmet need for adjuvant therapy administered following surgery to reduce the risk of the cancer spreading.

About EORTC1325/KEYNOTE-054

The KEYNOTE-054 clinical trial evaluated adjuvant therapy with Keytruda compared to placebo in patients with resected high-risk stage IIIA, B, or C melanoma.  In total, the study enrolled 1,019 patients who were treated with either Keytruda or a placebo for up to 1 year. This represents a total of 18 outpatient administrations.

This interim analysis demonstrates that Keytruda delayed the time to a melanoma recurrence.  Keytruda is the second “checkpoint inhibitor” demonstrated to improve the treatment of stage III melanoma.  The United States Food and Drug Administration recently granted approval to Opdivo (nivolumab), another “checkpoint inhibitor”  for the adjuvant treatment of melanoma.  Opdivo significantly improved recurrence-free survival at 18 months (66%) compared to standard treatment with Yervoy® (ipilimumab), (53%) in patients with resected Stage III or Stage IV melanoma.

Keytruda and Opdivo are both precision cancer medicines that belong to a new class of medicines called PD-1 inhibitors that have generated great excitement for their ability to help the immune system recognize and attack cancer. PD-1 is a protein that inhibits certain types of immune responses. Drugs that block PD-1 may enhance the ability of the immune system to fight cancer. These so call “checkpoint inhibitors” work by blocking PD-1.  Additional clinical trials will further evaluate how best to use these new medications; whether best used alone, or in combination, and the optimal duration of therapy remain unanswered questions.

References:

  1. http://www.mrknewsroom.com/news-release/oncology/mercks-Keytruda-pembrolizumab-significantly-improved-recurrence-free-survival-
  2. http://news.cancerconnect.com/fda-approves-opdivo-adjuvant-treatment-melanoma/

Copyright © 2018 CancerConnect. All Rights Reserved.